HL
NVO

Harding Loevner’s Novo Nordisk NVO Stock Holding History

Harding Loevner’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,583,302
Closed -$103M – 107
2015
Q4 		$103M Sell
3,583,302
-2,135,324
-37% -$59.1M 0.84% 48
2015
Q3 		$155M Buy
5,718,626
+183,620
+3% +$5.2M 1.25% 33
2015
Q2 		$152M Buy
5,535,006
+332,540
+6% +$9.35M 1.06% 39
2015
Q1 		$139M Buy
5,202,466
+393,872
+8% +$9.07M 1.06% 38
2014
Q4 		$102M Buy
4,808,594
+8,412
+0.2% +$188K 0.82% 49
2014
Q3 		$115M Buy
4,800,182
+756,910
+19% +$17.4M 0.85% 49
2014
Q2 		$93.4M Buy
4,043,272
+24,532
+0.6% +$542K 0.7% 51
2014
Q1 		$91.7M Buy
4,018,740
+1,057,470
+36% +$22.5M 0.7% 49
2013
Q4 		$54.7M Buy
2,961,270
+803,860
+37% +$14M 0.42% 59
2013
Q3 		$36.3M Sell
2,157,410
-506,130
-19% -$8.51M 0.32% 63
2013
Q2 		$42.8M Buy
+2,663,540
New +$44.3M 0.41% 59

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Harding Loevner's NVO Position: Q1 2016 in Review

Harding Loevner sold out of Novo Nordisk (NVO) in Q1 2016, closing a stake of 3,583,302 shares — an estimated $103M sold.

Harding Loevner first reported a position in NVO in Q2 2013 and held it in 11 quarters. The position peaked at $155M in Q3 2015. 535 funds tracked by Wall St. Rank hold NVO as of Q1 2016.

  • Harding Loevner reported no remaining Novo Nordisk position as of Q1 2016 after selling out during the quarter.
  • Harding Loevner sold 3,583,302 Novo Nordisk shares in Q1 2016, an estimated $103M.
  • Harding Loevner first reported a position in Novo Nordisk in Q2 2013 and held it in 11 quarters.
  • Harding Loevner's Novo Nordisk position peaked at $155M in Q3 2015.
  • 535 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2016.

Based on Harding Loevner's 13F filing for Q1 2016, filed 2 May 2016.